FY2025 EPS Estimates for Haemonetics Lowered by Analyst

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research reduced their FY2025 earnings estimates for Haemonetics in a research report issued to clients and investors on Wednesday, January 29th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $4.58 per share for the year, down from their prior estimate of $4.59. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.31 EPS, FY2026 earnings at $5.17 EPS and FY2027 earnings at $5.91 EPS.

A number of other analysts have also recently weighed in on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Wednesday, December 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a report on Tuesday, December 3rd. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Stock Down 0.8 %

HAE stock opened at $68.90 on Monday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics has a fifty-two week low of $67.26 and a fifty-two week high of $97.97. The firm’s 50-day simple moving average is $78.61 and its 200 day simple moving average is $79.15. The stock has a market cap of $3.46 billion, a PE ratio of 28.59, a price-to-earnings-growth ratio of 1.06 and a beta of 0.41.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.99 earnings per share.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Wellington Management Group LLP boosted its stake in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after buying an additional 363,702 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Haemonetics by 2.6% in the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after buying an additional 30,868 shares during the last quarter. Geode Capital Management LLC raised its holdings in Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after purchasing an additional 21,547 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the last quarter. Finally, Boston Trust Walden Corp raised its holdings in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.